Ripretinib
Sign in to save this workspacePrimary targets: C_KIT, PDGFRA, PDGFRB · FDA status: FDA Approved
Selectivity scorecard
KISS
92.95
Gini
0.674
CATDS
0.011
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Ripretinib. Strongest target: ARAF at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ARAF | 100.0% | 0.0% |
| 2 | BRAF | 100.0% | 0.0% |
| 3 | RAF1 | 100.0% | 0.0% |
| 4 | C_KIT | 99.3% | 0.7% |
| 5 | YSK4_MAP3K19 | 98.7% | 1.3% |
| 6 | ZAK_MLTK | 97.4% | 2.6% |
| 7 | LCK | 97.2% | 2.8% |
| 8 | FMS | 97.2% | 2.9% |
| 9 | DDR1 | 96.9% | 3.1% |
| 10 | EPHB1 | 96.5% | 3.5% |
| 11 | TAOK2_TAO1 | 96.4% | 3.6% |
| 12 | JAK1 | 96.0% | 4.0% |
| 13 | LYN | 95.3% | 4.7% |
| 14 | HIPK4 | 95.3% | 4.7% |
| 15 | EPHA2 | 95.2% | 4.8% |
| 16 | EPHB4 | 95.2% | 4.8% |
| 17 | DDR2 | 94.8% | 5.2% |
| 18 | MLK2_MAP3K10 | 94.7% | 5.3% |
| 19 | ABL2_ARG | 94.5% | 5.5% |
| 20 | EPHA6 | 94.1% | 5.9% |
Selectivity landscape
Where Ripretinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Ripretinib.
Annotations
Sign in to read and post annotations.
Loading…